目的:本研究研究考察了东东洋酮的神经药理学特性,一种生物活性化合物,使用体外治疗认知障碍,在硅,和斑马鱼胚胎毒性试验。
方法:该研究使用HPTLC估算了EA提取物中的Scopoletin浓度,使用2,2-二苯基-1-吡啶酰肼(DPPH)和血浆铁还原能力(FRAP)测定评估抗氧化性能,并使用生物信息学工具进行sopoletin目标。斑马鱼胚胎毒性(ZET)用于评估其毒理学特征。
结果:使用HPTLC对样品中0.0076%w/w的Scopoletin进行定量,对DPPH(0.5mM)和FRAP的进一步研究得出EC50分别为440.0μg/ml和84.29μg/ml。确定了12个与认知障碍(CI)相关的常见目标,以及可能的途径和分子相互作用。我们的结果表明,与ERAP1、SCN3A、和COMT。分子动力学模拟进一步证实了这些相互作用的稳定性。ZET评估显示450μg/ml浓度的EA提取物后的死亡率。
结论:该研究验证了在EA中存在Scopoletin,以及它们的靶标在神经发生和神经可塑性中起着至关重要的作用。ZET表现出浓度依赖性效应,强调在开发新制剂或治疗方法中剂量考虑的重要性。这项全面的研究有助于深入了解来自EA的Scopodetin对认知障碍的治疗潜力,为进一步研究铺平道路。
OBJECTIVE: This study investigates the neuropharmacologic properties of Scopoletin, a bioactive compound in Evolvulus alsinoides (EA) extract, for managing cognitive impairment using in-vitro, in-silico, and zebrafish embryo toxicity assays.
METHODS: The study estimates Scopoletin concentration in EA extract using
HPTLC, assesses antioxidant properties using 2,2-Diphenyl-1-picrylhydrazyl (DPPH) and ferric reducing ability of plasma (FRAP) assays, and uses bioinformatic tools for scopoletin targets. Zebrafish embryo toxicity (ZET) is used to assess its toxicological profile.
RESULTS: 0.0076% w/w Scopoletin in the samples was quantified using
HPTLC, further studies on the DPPH (0.5 mM) and FRAP gave EC50 at 440.0 μg/ml and 84.29 μg/ml respectively. Twelve common targets associated with cognitive impairment (CI) were identified, along with possible pathways and molecular interactions. Our results indicate significant binding affinities of Scopoletin with ERAP1, SCN3A, and COMT. Molecular dynamics simulations further confirm the stability of these interactions. ZET assessment demonstrated mortality after 450 µg/ml concentration of EA extract.
CONCLUSIONS: The study verifies the presence of Scopoletin in EA, along with their targets playing a crucial role in neurogenesis and neuroplasticity. The ZET demonstrated concentration-dependent effects, emphasizing the importance of dosage considerations in developing new formulations or therapeutics. This comprehensive study contributes valuable insight into the therapeutic potential of Scopoletin from EA for cognitive impairment, paving the way for further research.